Results 31 to 40 of about 12,593 (182)

Improved mitochondrial function underlies the protective effect of pirfenidone against tubulointerstitial fibrosis in 5/6 nephrectomized rats. [PDF]

PLoS ONE, 2013
Dysfunctional mitochondria participate in the progression of chronic kidney disease (CKD). Pirfenidone is a newly identified anti-fibrotic drug. However, its mechanism remains unclear.
Jun-Feng Chen, Hong Liu, Hai-Feng Ni, Lin-Li Lv, Ming-Hui Zhang, Ai-Hua Zhang, Ri-Ning Tang, Ping-Sheng Chen, Bi-Cheng Liu   +8 more
doaj   +1 more source

Assessing the impact of nintedanib and pirfenidone on lung function in idiopathic pulmonary fibrosis: A comprehensive meta-analysis [PDF]

Vojnosanitetski Pregled
Background/Aim. The incidence of idiopathic pulmonary fibrosis (IPF) has been increasing each year. Although pirfenidone and nintedanib were approved in 2014, they received only conditional recommendations, and no medication has yet been strongly ...
Luan Zhaoji, Muthal Amol, Sadar Smeeta
doaj   +1 more source

Histopathological evaluation of induced pulmonary fibrosis under the effect of montelukast

Al-Mustansiriyah Journal of Pharmaceutical Sciences, 2023
Pulmonary fibrosis (PF) is an interstitial lung disease leading to scarring of the lung. There are several types of lung fibrosis as familial pulmonary fibrosis, idiopathic pulmonary fibrosis, and others associated with non-specific   interstitial
Mohammed Rabah Mahdi, Wassan Abdul Kareem Abbas, Ghaith Ali Jasim   +2 more
doaj   +1 more source

Pirfenidone attenuates lung fibrotic fibroblast responses to transforming growth factor-β1

Respiratory Research, 2019
Background Pirfenidone, an antifibrotic agent used for the treatment of idiopathic pulmonary fibrosis (IPF), functions by inhibiting myofibroblast differentiation, which is involved in transforming growth factor (TGF)-β1-induced IPF pathogenesis. However,
Jin Jin, Shinsaku Togo, Kotaro Kadoya, Miniwan Tulafu, Yukiko Namba, Moe Iwai, Junko Watanabe, Kumi Nagahama, Takahiro Okabe, Moulid Hidayat, Yuzo Kodama, Hideya Kitamura, Takashi Ogura, Norikazu Kitamura, Kazuho Ikeo, Shinichi Sasaki, Shigeru Tominaga, Kazuhisa Takahashi   +17 more
doaj   +1 more source

Perils with Pirfenidone and “the tuberculosis link”

International Journal of Mycobacteriology, 2019
We report a case of idiopathic pulmonary fibrosis (IPF) treated with pirfenidone who developed tuberculosis (TB) and later had exfoliative dermatitis secondary to an interaction between pirfenidone and rifampicin. This case report highlights the possible
Madhav H Hande, K Vishak Acharya, A Shreenivasa, Kashinath Nayak, S Arun   +4 more
doaj   +1 more source

In vitro effects of pirfenidone on cardiac fibroblasts: proliferation, myofibroblast differentiation, migration and cytokine secretion.

PLoS ONE, 2011
Cardiac fibroblasts (CFs) are the primary cell type responsible for cardiac fibrosis during pathological myocardial remodeling. Several studies have illustrated that pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone) attenuates cardiac fibrosis in different
Qiang Shi, Xiaoyan Liu, Yuanyuan Bai, Chuanjue Cui, Jun Li, Yishi Li, Shengshou Hu, Yingjie Wei   +7 more
doaj   +1 more source

Potential Renoprotective Effect of Pirfenidone in Experimental Models of Acute and Chronic Kidney Disease

Ain Shams Medical Journal
Background: Pirfenidone is a pyridone compound with antioxidant and anti inflammatory properties. It has recently been investigated for renoprotective effects in acute kidney injury (AKI) and chronic kidney disease (CKD).Aim: To evaluate and compare the ...
Manal H. Albadawi, Mostafa Ezz, Ahmed Taha   +2 more
doaj   +1 more source

Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients

Therapeutic Advances in Respiratory Disease, 2020
Background: Pirfenidone is the first antifibrotic drug approved for the treatment of idiopathic pulmonary fibrosis (IPF) and it is used in the treatment of other interstitial pneumonias, such as unclassifiable interstitial lung disease (ILD) and ...
Haoshen Feng, Yabin Zhao, Zhenhua Li, Jian Kang   +3 more
doaj   +1 more source

Association of Elevated Platelets and C‐Reactive Protein With Severe Disease and Poor Survival in Systemic Sclerosis

Arthritis Care &Research, EarlyView.
Objective Elevated C‐reactive protein (CRP) levels in systemic sclerosis (SSc) have been linked with severe disease and worse survival, but the role of platelet levels remains unclear. This study examined whether elevated platelet levels, CRP levels, or both are associated with disease severity, progression, and survival in SSc.
Brian S. Lee, Shufeng Li, Srijana Davuluri, Jennifer Lee, Lorinda Chung   +4 more
wiley   +1 more source

Beyond Visual Scoring: Computational Computed Tomography Analysis for High‐Resolution Computed Tomography–Based Quantification of Interstitial Lung Disease in Inflammatory Rheumatic Disease

Arthritis Care &Research, EarlyView.
Interstitial lung disease (ILD) is a significant cause of morbidity and mortality in patients with inflammatory rheumatic disorders (IRDs). High‐resolution computed tomography (HRCT) is widely considered the gold standard for the noninvasive assessment of ILD; however, its interpretation is constrained by substantial interobserver variability and the ...
Alexander Pfeil, Tobias Hoffmann, Ulf Teichgräber, Diane Renz, Denise Beckmann, Gunter Wolf, Nicole Schadewaldt, Bianca Lassen‐Schmidt   +7 more
wiley   +1 more source